Introduction
Juvenile myoclonic epilepsy (JME) is the most common idiopathic generalized epilepsy (IGE) in adults, characterized by myoclonic jerks (MJ) on awakening, generalized tonic clonic seizures (GTCS) and typical absences in about one third of patients.
1-4 JME is equally prevalent amongst both the sexes and accounts for 10% of all epilepsies and up to 26% of all IGEs. 3 It is an age-dependent syndrome; absences, MJ and GTCS show a characteristic age related onset. [5] [6] [7] However 10% never develop GTCS. Genetically JME is determined by five Mendelian genes. 8 The EEG is usually abnormal in untreated patients. 3, 7 Paroxysmal abnormalities consist of generalized spike, polyspike and slow wave discharges (52%) (or) brief generalized bursts of sharp theta activity with interspersed small spikes (27%). Most of the discharges last for 1-3 (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] s. Focal clinical and EEG features were reported in up to 30% of patients with JME. 9, 10 Photosensitivity is age dependent and photo paroxysmal discharges were elicited in up to one third of patients. Although routine brain imaging is normal, abnormalities involving mesiofrontal cortical structures on magnetic resonance imaging (MRI) have been reported in some patients.
11
JME is considered to be a relatively benign form of IGE. Valproic acid (VPA) is the first drug of choice in JME and response to treatment is good to excellent; VPA effectively controls seizures in up to 80% of the patients with JME, but spontaneous remission is extremely rare. 12 Amongst patients with seizure relapse, discontinuation of medication is common reason, even after many years of seizure control. Fortunately, remission can be maintained for several years with appropriate medications. 13 Lamotrigine is a useful alternative in patients with JME who are intolerant to or develop side effects with VPA. In resistant cases the addition of small doses of lamotrigine to VPA is effective and it can be used as monotherapy. 14 On the contrary, VPA may not be the choice of drug in few patients due to reported side effects such as tremor, weight gain, alopecia and the risk of teratogenicity. 15 Topiramate and levetiracetam were shown to be well tolerated and effective in some patients with resistant JME or those intolerant to VPA. [16] [17] [18] True drug resistance in JME has been reported and ranges from 15 to 30%. 10, [19] [20] [21] [22] Delayed diagnosis of epilepsy, inappropriate AED treatment, high percentage of asymmetric (or) focal discharges on scalp EEG were factors responsible for intractable JME. Whilst the combined occurrence of all three seizure types and coexisting psychiatric disorders (PDs) were found to be risk factors associated with drug resistance in JME, 10, [19] [20] [21] there is paucity of literature confirming to what extent these factors increase the risk of lack of response, both as single entity or in combination with other clinical characteristics. If these factors were associated with lack of response to VPA in patients with JME, this may help to identify non-responders early and prescribe appropriate intervention. In the present study we analyse the factors associated with lack of response to VPA in patients with JME.
Materials and methods
A retrospective analysis of clinical and EEG data (January 2000 to January 2011) of all the patients with a diagnosis of JME, who were part of a larger epilepsy registry, and who were followed up for least 3 years was performed. The registry was maintained by the Neurologist (SJ) who is part of the comprehensive epilepsy care programme. The diagnosis and follow up of JME was made by SJ .The diagnosis of JME was based on International Classification of Epilepsies. 1 The inclusion criteria were: (1 Non availability of at least one EEG record for review. Data of patients who satisfied all the inclusion criteria for diagnosis of JME was obtained with uniform protocol for data collection. The study was approved by the institutional ethics committee. The data collected included, demographic data, semiology, type of seizures, time of occurrence of GTCS and MJ, precipitating factors, past history of febrile seizures, family history of epilepsy, imaging (CT/MRI) of brain (if performed), AED treatment details.
Psychiatric evaluation
All subjects were evaluated by a clinical psychologist, using International classification of psychiatric disorders (ICD-10) by a structured clinical interview method. Each patient can have more than one psychiatric diagnosis in Axis I disorders.
EEG
A 21 channel EEG recording was done according to international 10-20 system using Nicolet VEEG machine. Sleep deprived EEG (with 4 h sleep in the preceding 24 h) for 40 min (20 min sleep followed by 20 min awake or 40 min awake EEG) was performed including 3 min of hyperventilation (HV) and photic stimulation from 1 to 30 flashes/s without modifying the present AEDs. Filters used were 70 Hz and 0.5 Hz. The EEGs and the previous EEGs when available were read independently by two consultant neurologists without the knowledge of clinical history and findings with agreement were reported. The EEGs were always reviewed in more than one montage. EEG was classified as 'abnormal' only when definite bilaterally symmetrical, generalized spike-wave (or) polyspike and slow wave discharges (including photo paroxysmal response) were seen. EEGs were carefully evaluated for any focal abnormalities. EEG asymmetries were defined as asymmetry in the amplitude of generalized discharges of >50% or focal onset preceding the generalized discharges. Independent focal EEG abnormalities were defined as occurrence of independent focal spike/sharp wave discharges, focal slowing or phase reversals in the abnormal EEGs having generalized epileptiform discharges.
Treatment
All the patients received either VPA or lamotrigine or levetiracetam as the first line AED as per routine practice in our centre. The reasons for using lamotrigine or levetiracetam as first line AED included: VPA related adverse effects, women with child bearing potential. Topiramate was used in JME patients with associated migraine. The patients who received AED other than VPA were excluded from the study. None of our patients were on carbamazepine, phenytoin or phenobarbitone. VPA resistance was defined as persistent seizures (GTCS, absence seizures, MJ) despite use of maximum tolerated dose of VPA for the treatment of JME and adequate lifestyle. 21 Serum VPA levels were measured in 52 patients (including all with lack of response to VPA). The patients were divided into two groupsresponders to VPA (seizure free for two or more years) and those with lack of response to VPA (having moderate to poor seizure control despite optimal serum VPA level).
Statistical analysis
After confirming the homogeneity of the data, the differences between patients with response to VPA and those with lack of response were analysed using Chi square test for categorical variables and student un-paired t test for continuous variables. All the factors that were significantly different between the groups were tested for association with remission using spearman correlation. The effect size on lack of response to VPA was calculated for EEG abnormalities and PDs. Moreover, the sensitivity and specificity of factors associated with remission was analysed using ROC curves. All the statistical analysis was performed using Statistical Package for Social Sciences software version 17.0, IBM Computers, Illianos, Chicago, USA. A p < 0.05 was considered significant.
Results
There were a total of 269 patients with diagnosis of JME and accounted for 11.2% of the patients of the epilepsy registry. Of these 68 patients were excluded; the reasons being poor compliance and/or poor lifestyle (sleep deprivation and regular alcohol intake) in 19, inadequate dose of VPA in 6, AED used was lamotrigine in 16, levetiracetam in 22, and topiramate in 5. Finally 201 patients were included for analysis.
Baseline characteristics
Amongst the 201 patients, MJ were noted in all 201 patients. The baseline characteristics of the study population were shown in Table 1 . Focal features in semiology from history like head version, asymmetric tonic posturing or clonic movements of a limb in GTCS, asymmetric myoclonic jerks (as described by a relative or the patient) was noted in 32 patients (15.9%). Of the 201 patients who satisfied inclusion criteria, 163 (81%) of the patients had good response to VPA and were in remission, where as 38 (19%) patients had lack of response to VPA. The mean duration of follow up was 7.2 (range 3-12) years. The average age of the study population was 23 AE 9 years (Table 1) , however, the average age of the nonresponder group was higher (25 AE 9 vs. 22 AE 9; p = 0.053). There was no significant difference between the groups for gender distribution (Male -54.6% vs. 57.9%; p = 0.428), age of onset of epilepsy (<20 years, 84.5% vs.86.8%; p = 0.80), percentage of patients with duration of epilepsy for greater than two years (83.4% vs. 89.5%; p = 0.256), combination of all three types of seizures (19.6% vs. 26.3%; p = 0.240), family history of epilepsy (38.7% vs. 28.9%; p = 0.351) and fraction of patients with febrile seizures (12.9% vs. 8.7%; p = 0.146). Similarly, patients in both the groups were followed up for approximately same period of time (85.4 AE 25.6 vs. 86.4 AE 26.6 months; p = 0.788). Table 2 summarizes the difference between the two groups for all the clinical and demographic data.
EEG
The number of EEGs per patient ranged from 1 to 9 (mean 3.2). At least one abnormal EEG was noted in 134 patients (66.7%). All the 9 patients with only MJ had abnormal EEG. The PPR was positive in 26 patients (19.4%). Focal EEG abnormalities were noted 44 patients (32.8%). The various EEG abnormalities were calculated as a percentage of the 134 patients who had an abnormal EEG, not of the entire cohort. Table 3 shows various types of focal EEG abnormalities noted in EEGs with typical generalized epileptiform discharges. The occurrence of focal EEG abnormalities was significantly higher in VPA non-responders when compared to VPA responders (39.5% vs. 17.8%; p < 0.001).
Imaging
CT/MRI brain was available in 99 patients and was normal. All the patients with lack of response to VPA underwent brain MRI and it was normal.
Psychiatric evaluation
Psychiatric evaluation was suggestive of a significant psychiatric diagnosis in 67 (33.3%) patients in the entire cohort; 65.8% (25/ 38) of patients with lack of response to VPA were diagnosed to have a PDs, a significantly (p < 0.001) higher proportion than the VPA response group where only 42 out 163 (26.4%) patients were diagnosed to have PDs. Amongst the 67 patients with psychiatric diagnosis, anxiety disorders (generalized anxiety disorder (GAD), obsessive compulsive disorder (OCD) and phobic anxiety disorder) were more common and noted in 49.3% patients. Depressive disorder (mild to moderate depression, and dysthymia) was found in 38.8%; 7 patients had mixed anxiety with depression and schizophrenia was diagnosed in one (Table 1) . 
Treatment
Valproic acid was the first line AED used in all the patients; 163 (81%) were in remission. Amongst this group 2 patients with isolated MJ were off the AEDs for more than 5 years and seizure free. Thirty eight patients (19%) required more than one AED and were grouped as JME with lack of response to VPA. Serum VPA level was within reference range in all the patients with lack of response to VPA. The other AEDs given in addition to VPA were clobazam, clonazepam, lamotrigine, levetiracetam, zonisamide and topiramate; 28 were on combination therapy with 2 AEDs (7 patients were seizure free for more than one year) and 10 were on 3 AEDs.
While all the factors that were significantly different between the groups were analysed for association with lack of VPA response, diagnosis of PDs showed the strongest correlation with lack of response to VPA (r = 0.332; p < 0.0001). The diagnosis of PDs significantly increased the risk of VPA non-responsiveness by 5.54 times with 95% CI of 2.60-11.80 (p < 0.0001) but the other two factors that were significantly different between the groups namely, focal EEG abnormalities and the duration of epilepsy did not show significant correlations with lack of response to VPA. However focal EEG abnormalities were associated with lack of response to VPA by 3 times with 95% CI of 1.40-6.47 (p = 0.008). The relative risk ratio for lack of response to VPA is summarized in Table 4 .
Subsequently patients were divided in to four groups: patients with PDs alone, focal EEG abnormalities alone, PDs or focal EEG abnormalities, PDs and focal EEG abnormalities. ROC curves were plotted for lack of response to VPA for the above mentioned four groups showed, that diagnosis of PDs was sensitive to lack of response to VPA with an area under curve of 0.700; p < 0.0001; furthermore, occurrence of focal EEG abnormalities or PDs had an area under curve of 0.725; p < 0.0001. On the contrary, presence of focal EEG abnormalities alone (AUC 0.608; p = 0.04) or presence of focal EEG abnormalities along with PDs in a combination (AUC 0.584; p = 0.108) were not sensitive to detect lack of response to VPA. Fig. 1 summarizes the ROC curves of the variable assessed in the study cohort.
Discussion
The current study conducted at a tertiary referral care in South India, shows an incidence of JME of 11.2%, similar to the prevalence reported elsewhere in the world.
7 Importantly, the current study has shown that irrespective of other clinical features and/or investigations; diagnosis of PDs may anticipate lack of response to VPA. The present study reflects a typical JME population with characteristics similar to other studies reported previously. 7, 13, [23] [24] [25] The combination of absence seizures with GTCS and MJ was seen in 20.9% as described before. 8, 26 On the contrary, incidence of febrile convulsions in the present study was higher than that reported by Janz et al. reflecting some ethnic variation or ascertainment bias. 25 Family history of epilepsy was noted in 36.8% which was similar to a study from India. 27 EEG was abnormal in 66.7% in the present study, lesser when compared to previous studies. It could be due to the reason that most of the EEGs were done when the patients were on AEDs. Focal EEG abnormalities were seen in 44% which was higher when compared to a study by Aliberti et al. 9 JME is considered to have relatively good seizure outcome. True resistance to VPA monotherapy is uncommon. Drug resistance in JME should be considered after excluding the causes of pseudo resistance which may be due to wrong AED choice, inadequate lifestyle and poor compliance. Previous studies showed that 70-80% of JME population was controlled on VPA monotherapy. 7, 22 Similarly, in the present study 81% of patients responded to VPA monotherapy. Psychiatric disorders and focal EEG abnormalities were associated with lack of response to VPA monotherapy. Gelisse et al., in 2001 , in a study of 155 JME patients reported pseudo resistance in 9.7% and true resistance in 15.5%. 21 They found that the predictors of drug resistance were presence of psychiatric problems and the combination of all three seizure types. In recent study prolonged duration of epilepsy, combination of all three seizure types and epileptiform discharges in baseline EEG were associated with poor seizure control on VPA monotherapy or polytherapy. They also found that compared to seizurefree patients, those with persistent seizures were of younger age at epilepsy onset and had higher prevalence of personality disorders. 28 The current study, however found that co-existing PDs were strongly associated with lack of response to VPA in JME patients. Focal EEG abnormalities though increased the chances, did not correlate with lack of response to VPA; moreover there was no correlation between lack of response to VPA and duration of epilepsy, family history of epilepsy, age at onset and combination of all three types of seizures. In a long-term follow up study 32.5% of JME patients continued to have seizures despite multiple AEDs; the occurrence of GTCS preceded by bilateral MJs and complete remission of GTCS under AEDs significantly increased the chance for complete seizure freedom. 29 It has been reported that patients Table 4 Odds Ratio to detect lack of response to VPA using EEG abnormalities and psychiatric disorders (n = 201). with absence seizures and MJ or isolated MJ show an excellent response to VPA monotherapy, similar to the present study. 20, 30 Patients with JME show focal clinical and EEG features which should not be misinterpreted as indicative of partial epilepsy. In a follow up study of 33 patients with JME at Duke epilepsy centre, 30% were VPA resistant; EEG asymmetries were noted in 40% of VPA resistant group when compared to 10% in VPA sensitive JME patients. 22 They also found that auras, post-ictal confusion and intellectual deficiency were more common in VPA resistant group. However in another study EEG asymmetries were not associated with resistance to treatment. 31 We followed strict inclusion criteria and one of them was no evidence of intellectual deficit. In the present study focal EEG abnormalities increased the chances but did not correlate with lack of response to VPA. The possible mechanisms for these focal EEG features include imbalance between both the cerebral hemispheres, focal cortical pathology like microdysgenesis and development over time of localized, selfsustaining hyperexcitability in low-threshold cortical structures subjected to genetic and environmental factors. 32 Association of PDs has been described in 26.5-49% of patients with JME. [33] [34] [35] [36] They include anxiety disorders, mood disorders and personality disorders. We noted PDs in 33.3% with JME. The prevalence of PDs was 26.5% in patients with JME when evaluated using DSM IV in a cohort of 170 patients. 34 We noted that anxiety disorders (49.3%) were more frequent than depressive disorders in JME. In a study from Brazil the prevalence of PDs in JME was 49%. Anxiety and mood disorders (23% and 19%, respectively) were the most common and a statistically significant association between anxiety disorders and JME was noted. 35 We noted a significant association between PDs and lack of response to VPA. Psychiatric evaluation and a diagnosis of co-existing PDs may anticipate lack of response to VPA early in these patients. Coexistence of PDs in JME has been found to be associated with increased seizure frequency and poor therapeutic control. 21, 36 Baykan et al. observed trueresistant course in 16.7% of JME patients and it was significantly associated with PDs and presence of thyroid disease. 37 There are no studies till date determining the association of combined focal EEG abnormalities and PDs with drug resistant JME. We found that presence of focal EEG abnormalities does not add significantly more to presence of PDs alone in estimating the probability of lack of response to VPA.
Limitations
Despite the best of the cautions exercised, the following are the limitations of the study. First, a small sub group of patients did not receive VPA. Secondly we did not include patients on lamotrigine and levetiracetam as monotherapy, which are emerging as good alternatives to VPA especially in women with child bearing potential. Thirdly we ascertained focal features based on EEG rather than video EEG recordings. However, the findings of the current study are plausible in clinical context where in most of the demographic data in the current study is in concordance with existing literature, more over 81% responded to VPA monotherapy, a number that mirrors findings reported by previous investigators.
Conclusion
Juvenile myoclonic epilepsy is well controlled with VPA. There is a sub group of patients with JME who lack response to VPA. We found that PDs are associated with lack of response to VPA. Psychiatric disorders in JME may anticipate lack of response if they occur prior to the onset of refractoriness, there by avoid delays in initiating appropriate drug management in these patients. The treating physician should be careful in this subset of patients before informing the newly diagnosed JME patients that their epilepsy has good outcome.
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